噻氯匹定和肠溶阿斯匹林防治高危患者脑卒中的研究

CLINICAL STUDY OF STROKE PREVENTION WITH TICLODIPINE AND ENTERIC ASPIRIN IN HIGH-RISK PATIENTS

应用同一人群分组对照群组研究的方法,在我院三门诊患者中,检出服噻氯匹定(抵克立得,TIC,0.125～0.25g/d)的全部患者60例,随机挑选服 AS A(0.05～0.3g/d)者51例,分别平均随访10.6和10.4日,比较他们预防再发短暂脑供血不足(TIA)和脑卒中的疗效。结果显示 TIC 比 ASA减少再发性 TIA 和脑卒中的相对危险性71%(不分性别)。TIC 对此,治疗后比治疗前减少82.7%,但ASA 治疗后比治疗前只下降10.3%。TIC 防治再发性 TIA 和脑卒中的疗效显著,小剂量应用副作用小,值得推广。

Clinical efficacies of ticlodipine and enteric aspirin(ASA)have been compared for the prevention of transient ischemic attack(TIA)and stroke in the same high- risk outpatient population,enolled in the study in the 3rd outpatient department.Total 60 patients taking ticlodipine(0.05～0.3 g/d)and 51 randomly chosen to receive enteric as- pirin were followed up for average 10.6 and 10.4 months respectively.Significant benefit was observed in ticlodipine group with relative risk of TIA relapse stroke reduced by 71% (for both sexes)as compared with that in group.In ticlodipine group,the relative risk of TIA relapse/stroke before and after treatment was reduced by 82.7%(10.3% in ASA group).Few side effects with small dose ticlodipine were reported.